Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Yukio Kondo, Noam Benyamini(Tel Aviv University), Andrew Lim(Austin Hospital), Kenshi Suzuki(Jikei University School of Medicine), Takayuki Ishikawa(Kobe City Medical Center General Hospital), Mohammed Z.H. Farooqui(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jesús F. San Miguel(Clinica Universidad de Navarra), Katja Weisel(Universität Hamburg), Sagar Lonial(Emory University), Alessandra Larocca(Cornell University), Thierry Façon(Université de Lille), Habte Yimer(Texas Oncology), Hila Magen‐Nativ(Rabin Medical Center), Michel Attal(Université Fédérale de Toulouse Midi-Pyrénées), Trish Walker, Sundar Jagannath(Mount Sinai Hospital), Robert McCroskey(Northwest Medical Specialties), Patricia Marinello(Merck & Co., Inc., Rahway, NJ, USA (United States)), Naoki Takezako(National Disaster Medical Center), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Donna Reece(Princess Margaret Cancer Centre), Lionel Karlin(Hôpital Lyon Sud), Mohamed Elemary(University of Saskatchewan), Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States)), Albert Oriol(Institut Català d'Oncologia), Monika Engelhardt(University Medical Center Freiburg), Michèle Cavo(Unknown), Fredrik Schjesvold(Oslo University Hospital), Shinsuke Iida(Nagoya City University Hospital), Irit Avivi(Tel Aviv Sourasky Medical Center), Andrew J. Nicol(The University of Queensland), Andréas Mackensen(University Medical Center Freiburg), Hiroshi Kosugi(Ogaki Municipal Hospital), Jean Samuel Boudreault Pedneault, Morio Matsumoto(Keio University Hospital), John Quinn, Amos Cohen(Hospital for Sick Children), Richard LeBlanc(Hôpital Maisonneuve-Rosemont), George Grigoriadis(Hudson Institute of Medical Research)
Cited by 247
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k